Cost Management Insights: SG&A Expenses for Alkermes plc and Soleno Therapeutics, Inc.

Navigating SG&A Expenses: A Tale of Two Companies

In the ever-evolving landscape of the pharmaceutical industry, effective cost management is crucial. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of Alkermes plc and Soleno Therapeutics, Inc. from 2014 to 2023. Over this period, Alkermes plc has seen a steady increase in SG&A expenses, peaking at approximately $690 million in 2023, marking a 245% rise from 2014. In contrast, Soleno Therapeutics, Inc. has maintained a more modest trajectory, with expenses growing from around $2.9 million in 2014 to $13.5 million in 2023, a 360% increase. This stark difference highlights the varying scales and strategies of these companies. While Alkermes focuses on expansive growth, Soleno's leaner approach may offer insights into efficient cost management for smaller firms. Understanding these trends is vital for stakeholders aiming to optimize financial strategies in the pharmaceutical sector.